AVBPArriVent BioPharma, Inc.同业对比
ArriVent BioPharma, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVBP本股 | $1.4B#7 | — | 3.7x#8 | — | — | -106.6%#10 | — | -45.3%#11 | — | — | 52.3%#7 | — |
| INVA | $1.5B#1 | 4.9x#3 | 1.2x#2 | 3.7x#3 | 14.7%#4 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#2 | 5#2 | — | — |
| DMRA | $1.5B#2 | 3.2x#2 | 2.9x#5 | — | — | -878.8%#12 | — | -40.7%#10 | — | — | 751.8%#2 | — |
| BCAX | $1.5B#3 | — | 3.1x#6 | — | — | -102.9%#9 | — | -29.4%#7 | — | — | 95.6%#6 | — |
| XERS | $1.4B#4 | — | — | 4.9x#5 | 43.7%#1 | 101.0%#2 | 8.5%#3 | — | 20.6%#1 | — | 4.4%#9 | — |
| TRAX | $1.4B#5 | — | 8.3x#11 | — | — | — | — | 0.0%#2 | — | — | — | — |
| LBRX | $1.4B#6 | 1.9x#1 | 4.1x#9 | — | — | 60.1%#5 | — | -7.6%#5 | — | — | 170.5%#5 | — |
| ORIC | $1.3B#8 | — | 3.4x#7 | — | — | -1.3%#7 | — | -34.0%#9 | -40.4%#5 | — | 15.1%#8 | — |
| HROW | $1.3B#9 | — | 84.4x#12 | 4.7x#4 | 36.4%#2 | 70.6%#4 | 11.2%#2 | -33.8%#8 | 13.2%#3 | 6#1 | — | — |
| RARE | $1.3B#10 | — | — | 1.9x#1 | 20.2%#3 | -1.1%#6 | -79.5%#5 | — | — | — | -56.3%#10 | — |
| OMER | $1.3B#11 | 10.0x#4 | — | 17.0x#6 | -34.0%#6 | 97.9%#3 | -166.4%#6 | — | -151.8%#6 | — | 328.7%#4 | — |
| AKTS | $1.2B#12 | — | 2.5x#3 | — | — | — | — | 0.0%#2 | — | — | 23319.4%#1 | — |
| OPK | $1.2B#13 | — | 1.0x#1 | 2.0x#2 | -14.9%#5 | -324.0%#11 | -19.3%#4 | -19058.1%#12 | -13.3%#4 | 4#3 | — | — |
| SPTX | $1.2B#14 | — | 2.8x#4 | — | — | — | — | 0.0%#2 | — | — | — | — |
| ANRO | $1.2B#15 | — | 5.4x#10 | — | — | -2.9%#8 | — | -28.8%#6 | — | — | 664.8%#3 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议